{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T21:45:59Z","timestamp":1783806359235,"version":"3.55.0"},"reference-count":47,"publisher":"VM Media SP. zo.o VM Group SK","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","oncology-and-radiotherapy.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.rpor.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T21:46:36Z","timestamp":1492465596000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dose to organ at risk and dose prescription in liver SBRT"],"prefix":"10.5603","volume":"22","author":[{"given":"Rives","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izar","family":"Fran\u00e7oise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parent","family":"Laure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modesto","family":"Anouchka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portier","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirzin","family":"Sylvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3595","reference":[{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/107327481001700206","article-title":"Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity","volume":"17","author":"Sawrie","year":"2010","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0245","first-page":"649","article-title":"Improved radiotherapy for primary and secondary liver cancer: stereotactic body radiation therapy","volume":"32","author":"Tao","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.rpor.2017.03.001_bib0250","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000078271","article-title":"Stereotactic radiation therapy of liver metastases: update of the initial phase-I\/II trial","volume":"38","author":"Herfarth","year":"2004","journal-title":"Front. Radiat. Ther. Oncol."},{"issue":"7","key":"10.1016\/j.rpor.2017.03.001_bib0255","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/02841860600904821","article-title":"Stereotactic radiotherapy of primary liver cancer and hepatic metastases","volume":"45","author":"Wulf","year":"2006","journal-title":"Acta Oncol."},{"issue":"6","key":"10.1016\/j.rpor.2017.03.001_bib0260","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ejca.2010.01.008","article-title":"Muacevic a. Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients","volume":"46","author":"Stintzing","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijrobp.2012.12.021","article-title":"Is stereotactic body radiation therapy an attractive option for unresectable liver metastases?. A preliminary report from a phase 2 trial","volume":"86","author":"Scorsetti","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.rpor.2017.03.001_bib0270","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/02841869509127197","article-title":"Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients","volume":"34","author":"Blomgren","year":"1995","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0167-8140(00)00226-7","article-title":"Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame","volume":"57","author":"Wulf","year":"2000","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.rpor.2017.03.001_bib0280","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2006.10.025","article-title":"Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases","volume":"67","author":"Katz","year":"2007","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0285","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-015-0369-9","article-title":"Stereotactic radiation therapy for liver metastases: factors affecting local control and survival","volume":"10","author":"Andratschke","year":"2015","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"Barney","year":"2012","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.rpor.2017.03.001_bib0295","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol (Madr)"},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0300","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.semradonc.2008.04.005","article-title":"The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery","volume":"18","author":"Kirkpatrick","year":"2008","journal-title":"Semin. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijrobp.2013.03.013","article-title":"Radiobiology of stereotactic body radiation therapy\/stereotactic radiosurgery and the linear-quadratic model","volume":"87","author":"Song","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2013.07.022","article-title":"The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?","volume":"88","author":"Brown","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.rpor.2017.03.001_bib0320","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A Phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","author":"Schefter","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijrobp.2008.03.062","article-title":"Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy","volume":"73","author":"McCammon","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"17","key":"10.1016\/j.rpor.2017.03.001_bib0330","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"issue":"2, Suppl.","key":"10.1016\/j.rpor.2017.03.001_bib0335","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/j.ijrobp.2013.06.836","article-title":"Inter- and intraobserver variability in daily tumor setup using contrast-enhanced CT scans for patient positioning during stereotactic body radiation therapy for liver metastases","volume":"87","author":"Mendez Romero","year":"2013","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0340","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1748-717X-7-92","article-title":"Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases \u2013 clinical results","volume":"7","author":"Boda-Heggemann","year":"2012","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.rpor.2017.03.001_bib0345","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/02841860600904870","article-title":"Interim analysis of a prospective phase I\/II trial of SBRT for liver metastases","volume":"45","author":"Kavanagh","year":"2006","journal-title":"Acta Oncol (Madr)"},{"issue":"3","key":"10.1016\/j.rpor.2017.03.001_bib0350","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2011.07.020","article-title":"Radiotherapy for liver metastases: a review of evidence","volume":"82","author":"H\u00f8yer","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0355","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2012.08.043","article-title":"Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities","volume":"87","author":"Klein","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.rpor.2017.03.001_bib0360","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase i study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.rpor.2017.03.001_bib0365","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0370","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0375","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0380","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semradonc.2011.05.003","article-title":"Hepatic radiation toxicity: avoidance and amelioration","volume":"21","author":"Guha","year":"2011","journal-title":"Semin. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0385","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canrad.2010.11.005","article-title":"Radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques des m\u00e9tastases h\u00e9patiques","volume":"15","author":"De Bari","year":"2011","journal-title":"Cancer\/Radioth\u00e9rapie"},{"issue":"3, Suppl.","key":"10.1016\/j.rpor.2017.03.001_bib0390","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2009.06.092","article-title":"Radiation-associated liver injury","volume":"76","author":"Pan","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.rpor.2017.03.001_bib0395","first-page":"236","article-title":"The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?","volume":"5","author":"Thomas","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.rpor.2017.03.001_bib0400","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.prro.2013.12.004","article-title":"Liver toxicity prediction with stereotactic body radiation therapy: the impact of accounting for fraction size","volume":"4","author":"Murphy","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"4\u20135","key":"10.1016\/j.rpor.2017.03.001_bib0405","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.canrad.2010.02.013","article-title":"Dose de tol\u00e9rance \u00e0 l\u2019irradiation des tissus sains: le foie","volume":"14","author":"De Bari","year":"2010","journal-title":"Cancer\/Radioth\u00e9rapie"},{"issue":"2","key":"10.1016\/j.rpor.2017.03.001_bib0410","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijrobp.2013.10.045","article-title":"Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA","volume":"88","author":"Sanuki","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"26","key":"10.1016\/j.rpor.2017.03.001_bib0415","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.55.4675","article-title":"Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice","volume":"32","author":"Timmerman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.rpor.2017.03.001_bib0420","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2014.11.028","article-title":"Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract","volume":"91","author":"Osmundson","year":"2015","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.rpor.2017.03.001_bib0425","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijrobp.2010.03.020","article-title":"Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver","volume":"80","author":"Andolino","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0430","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","volume":"53","author":"Dawson","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0435","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0360-3016(02)02846-8","article-title":"Analysis of radiation-induced liver disease using the Lyman NTCP model","volume":"53","author":"Dawson","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0440","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.rpor.2017.03.001_bib0445","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1748-717X-8-113","article-title":"Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma \u2013 benchmark for a prospective multi-institutional study","volume":"8","author":"Eriguchi","year":"2013","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0450","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"Kopek","year":"2010","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.rpor.2017.03.001_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.rpor.2017.03.001_bib0460","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2012.06.005","article-title":"Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies","volume":"84","author":"Bae","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.rpor.2017.03.001_bib0465","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I\u2013II study","volume":"45","author":"M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol."},{"issue":"7","key":"10.1016\/j.rpor.2017.03.001_bib0470","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cncr.28515","article-title":"Stereotactic body radiotherapy: a critical review for nonradiation oncologists","volume":"120","author":"Kirkpatrick","year":"2014","journal-title":"Cancer"}],"container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136717300172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136717300172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T14:14:19Z","timestamp":1613657659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1507136717300172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1507136717300172"],"URL":"https:\/\/doi.org\/10.1016\/j.rpor.2017.03.001","relation":{},"ISSN":["1507-1367"],"issn-type":[{"value":"1507-1367","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose to organ at risk and dose prescription in liver SBRT","name":"articletitle","label":"Article Title"},{"value":"Reports of Practical Oncology & Radiotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpor.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o.","name":"copyright","label":"Copyright"}]}}